Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
The European Commission (EC) granted marketing authorisation for Celltrion’s regdanvimab following a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) last week
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
The interim data combines three mRNAs into one therapy injected directly into the tumour
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
